Source: http://www.google.de/patents/US20020169504?hl=de
Timestamp: 2013-05-24 17:27:00
Document Index: 62771350

Matched Legal Cases: ['art 10', 'art 10', 'art 10', 'art 10', 'art 10', 'art 10']

Patent US20020169504 - Mitral valve therapy device, system and method - Google PatenteSuche Bilder Maps Play YouTube News Gmail Drive Mehr » Erweiterte Patentsuche | Webprotokoll | Anmelden Erweiterte Patentsuche PatenteAn assembly and method for effecting the condition of a mitral valve annulus of a heart includes a guide wire configured to be fed into the coronary sinus of the heart, and a mitral valve annulus therapy device configured to be slidingly received on the guide wire and advanced into the coronary sinus...http://www.google.de/patents/US20020169504?utm_source=gb-gplus-sharePatent US20020169504 - Mitral valve therapy device, system and method Ver�ffentlichungsnummerUS20020169504 A1PublikationstypAnmeldung Ver�ffentlichungsdatum14. Nov. 2002Eingetragen14. Mai 2001 Priorit�tsdatum14. Mai 2001Auch ver�ffentlicht unterCA2447689A1CA2447689CEP1395202A2EP1395202A4EP1395202B1US6800090US7270676US7828843US20050027351US20050027353US20050033419US20050038507WO2002100240A2WO2002100240A3 Ver�ffentlichungsnummerUS 2002/0169504 A1US2002/0169504A1 ErfinderJohn AdamsClifton AlfernessJohn PowerUrspr�nglich Bevollm�chtigterCardiac Dimensions, Inc. US-Klassifikation623/2.36606/151Internationale KlassifikationA61F2/24 UnternehmensklassifikationA61F2/2451 Europ�ische KlassifikationA61F 2/24R4Referenzen Referenziert von (42)Externe LinksUSPTO USPTO-Zuordnung EspacenetMitral valve therapy device, system and methodUS 20020169504 A1 Zusammenfassung An assembly and method for effecting the condition of a mitral valve annulus of a heart includes a guide wire configured to be fed into the coronary sinus of the heart, and a mitral valve annulus therapy device configured to be slidingly received on the guide wire and advanced into the coronary sinus of the heart on the guide wire. A guide tube may further be employed for guiding the device into the coronary sinus. An introducer which may be employed for pushing the device into or pulling device out of the heart has a mechanism for releasably locking to the device. This enables substitution of the device if needed. Also, the crossover point of the circumflex artery and coronary sinus may be determined and avoided when the device is deployed. Zeichnungen(6) Anspr�che
DETAILED DESCRIPTION OF THE INVENTION [0045] Referring now to FIG. 1, it is a superior view of a human heart 10 with the atria removed to expose the mitral valve 12, the coronary sinus 14, the coronary artery 15, and the circumflex artery 17 of the heart 10 to lend a better understanding of the present invention. Also generally shown in FIG. 1 are the pulmonary valve 22, the aortic valve 24, and the tricuspid valve 26 of the heart 10. [0046] The mitral valve 12 includes an anterior cusp 16, a posterior cusp 18 and an annulus 20. The annulus encircles the cusps 16 and 18 and maintains their spacing to provide a complete closure during a left ventricular contraction. As is well known, the coronary sinus 14 partially encircles the mitral valve 12 adjacent to the mitral valve annulus 20. As is also known, the coronary sinus is part of the venus system of the heart and extends along the AV groove between the left atrium and the left ventricle. This places the coronary sinus essentially within the same plane as the mitral valve annulus making the coronary sinus available for placement of the mitral valve therapy device of the present invention therein. [0047] of particular importance is the physiological relationship of the coronary sinus 14 and the circumflex artery 17. The circumflex artery 17 branches from the coronary artery 15 and supplies blood flow to critical tissue of the heart 10. The circumflex artery passes beneath the coronary sinus 14 at a crossover point 19. It is one aspect of the present invention to avoid constriction of blood flow through the circumflex artery 17 when a mitral valve therapy device is deployed in the coronary sinus 14. [0048]FIG. 2 shows a mitral valve therapy device 30 embodying the present invention. As may be noted in FIG. 2, the device is elongated and has an arched configuration to at least partially encircle the mitral valve 12 adjacent to the mitral valve annulus 20 when implanted in the coronary sinus 14. The device 30 has an unstressed preformed arched radius smaller than the radius of the dilated mitral valve annulus 20. This causes the device 30 to constrict the mitral valve annulus and impart an inward, generally radial force designated by arrows 32 on the mitral valve annulus 20 when implanted in the coronary sinus of the heart. This force reshapes and returns the mitral valve annulus 20 to its original or substantially original geometry to permit the cusps 16 and 18 to more fully come together for sealing the left atrium during left ventricular contraction. [0049] The device 30 has a cross section dimension to be received by the coronary sinus. It is preferably formed of a resilient material permitting the device to be straightened and/or bent for being advanced into the coronary sinus. After being positioned within the coronary sinus, the device is permitted to assume its preformed arched configuration to act upon the mitral valve annulus as previously described. To that end, the device may be formed of, for example, Nitinol, a nickel titanium alloy, well known in the art. This material, as is well known, is capable of being preformed but manipulated to be straight or partially bent while having sufficient memory to return to its preformed configuration. Stainless steel is also among the materials which may be used in forming the device 30. In order to be received within the coronary sinus, the device may have a cross sectional dimension of, for example, on the order of four or five french. [0050] With continued reference to FIG. 2, the device 30 has a distal end 34 and a proximal end 36. Between the distal end 34 and proximal end 36 the device further includes a channel 38 which is aligned with a bore 40 extending through the distal end 34 and a bore 42 extending through the proximal end 36. The proximal end 36 further includes an integral sleeve 44 which carries a protruding locking pin 46. As will be seen subsequently, the bores 40 and 42 permit the device to be slidingly received by a guide wire during deployment of the device 30. The guide wire, during deployment, is confined within the channel 38. [0051]FIGS. 3 and 4 illustrate an assembly 50 for deploying or implanting the mitral valve therapy device 30. The assembly 50 includes a guide wire 52, a guide tube 54, and an elongated introducer 56. [0052] The guide wire 52 is preferably an elongated coil. It has an outer dimension to permit the guide wire 52 to be passed through the bores 40 and 42 of the device 30. This enables the device 30 to be slidingly received on the guide wire 52 with the guide wire confined within the channel 38 of the device 30. [0053] The guide tube 54 is elongated and formed of a flexible biocompatible material. It includes an inner lumen 55 permitting the device 30 and the introducer 56 to be received therein. [0054] The introducer 56 preferably takes the form of an elongated coil having an inner channel dimensioned to be received by and slid onto the guide wire 52. At a distal end 58 the introducer includes a sleeve 60 which may be received over the sleeve 44 of the device 30. The introducer sleeve 60 includes a detented slot 62 for releasably receiving the pin 46 of the device 30. This enables the introducer 56 to be releasably locked to the device 30 during deployment of the device. It also permits the introducer to be relocked to the device 30 for extracting the device should it be necessary to remove the device 30 for exchange with another device. [0055] As previously mentioned, the circumflex artery 17 passes under the coronary sinus 14. When the device 30 is deployed, it should not be permitted to exert a force from the coronary sinus against the circumflex artery. Hence, in accordance with one embodiment of the present invention, the device is implanted within the coronary sinus at a position whereby the distal end 34 of the device 30 is proximal to the crossover point of the circumflex artery and the coronary sinus. This requires determination of the crossover point. FIGS. 5 and 6 illustrate how such a determination may be made in accordance with the present invention. [0056] A first elongated member, such as an elongated wire or coil wire 70 is inserted into the circumflex artery 17. The wire 70 may be formed of a material visible under X ray fluoroscopy or be of other material having a coating which is visible under X ray fluoroscopy. Next, a second wire which may be the guide wire 52 is inserted into the coronary sinus 14 by way of the ostium of coronary sinus 13. Again, the wire 52 is preferably of a material visible under X ray fluoroscopy or of another material having a coating which is visible under X ray fluoroscopy. Preferably, the wires 52 and 70 are elongated coils formed of stainless steel. [0057] The heart 10 or at least that portion of the heart 10 where the circumflex artery passes under the coronary sinus is subjected to X ray fluoroscopy. X ray fluoroscopy is well known in the art. The crossover point 19 where the wires 52 and 70 cross and hence where the circumflex artery and coronary sinus cross may then be readily observed by X ray fluoroscopic examination. This locates the crossover point 19 which is to be distal to the distal end 34 of the device 30 when the device 30 is positioned within the coronary sinus. [0058] Once the crossover point 19 has been determined, the device 30 may be deployed. During the deployment of the device, the first wire 70 may be left in the circumflex artery to permit continuous X ray fluoroscopic examination or later X ray fluoroscopic examination to confirm proper device positioning. [0059]FIG. 7 shows how the assembly 50 may be used to implant the device 30. Presumably the guide wire 52 has already been positioned in the coronary sinus 14 to support the determination of the circumflex artery and coronary sinus crossover point as described above. As also described above, wire 70 may also be left in the heart at this time. [0060] Next, the guide tube 54 is advanced into the heart. The guide tube is advanced over the guide wire 52. The guide wire hence guides the guide tube 54 into the coronary sinus where the device is to be implanted. [0061] When the guide tube 54 is positioned in the coronary sinus, the device 30 and introducer 56 are then advanced into the guide tube 54 and over the guide wire 52. The distal end 58 of the introducer 56 is first releasably locked to the proximal end 36 of the device 30 (FIGS. 3 and 4) by advancing the sleeve 60 of the introducer 56 over the sleeve 44 of the device 30 and inserting the locking pin 46 in the detented locking groove 62. [0062] With the distal end of the introducer 56 thus engaged with the proximal end of the device 30, the device may then be pushed by the introducer 56 into the coronary sinus 14 while being guided by both the guide wire 52 and the guide tube 54. [0063] When the device is positioned within the coronary sinus 14 with its distal end proximal to the crossover point 19 and its position is confirmed by X ray fluoroscopy, the introducer may be removed. This is accomplished by turning the introducer to unlock the pin 46 and retracting the introducer from the guide tube. Then, the guide tube 54 may also be retracted leaving the device in place but still on the guide wire 52. The performance of the device 30 may now be evaluated. If another device of different properties is deemed more appropriate, the device may be readily replaced. Thus is accomplished by reinserting the guide tube over the device, reinserting the introducer, locking the introducer to the device, and removing the device through the guide tube with the introducer. A new device may then be deployed as previously described. [0064] Once a device is deployed that satisfies the requirements of the procedure, the guide wire 52, and the wire 70 if still within the heart, may be removed. This leaves the device 30 in its proper position as illustrated in FIG. 8. Here it may be seen that the device 30 partially encircles the mitral valve 12 within the coronary sinus 14 and adjacent to the mitral valve annulus. The distal end 34 of the device 30 is proximal to the crossover point 19. The proximal end 36 of the device protrudes slightly into the right atrium (not shown) through the ostium of coronary sinus 13. The sleeve 44 and pin 46 remain should subsequent removal of the device be deemed necessary. [0065]FIG. 9 shows another mitral valve therapy device 130 embodying the present invention. As may be noted in FIG. 9, the device is elongated and has an arched configuration to at least partially encircle the mitral valve 12 adjacent to the mitral valve annulus 20 when implanted in the coronary sinus 14. The device 130 has an unstressed preformed arched radius smaller than the radius of the dilated mitral valve annulus 20 to impart an inward, generally radial force when implanted in the coronary sinus of the heart as shown. This force again returns the mitral valve annulus 20 to its original or substantially original geometry to permit the cusps 16 and 18 to more fully come together for sealing the left atrium during left ventricular contraction. [0066] The device 130 has a cross sectional dimension to be received by the coronary sinus. It is also preferably formed of a resilient material to permit the device to be straightened and/or bent for being advanced into the coronary sinus. After being positioned within the coronary sinus, the device is permitted to assume its preformed arched configuration to act upon the mitral valve annulus as previously described. To that end, the device may be formed of, for example, Nitinol, a nickel titanium alloy. [0067] The device 130 has a distal end 134 and a proximal end 136. Between the distal end 134 and proximal end 136 the device further includes a channel 138 which is aligned with a bore 140 extending through the distal end 134 and a bore 142 extending through the proximal end 136. The proximal end 136 further includes an integral sleeve 144 which carries a protruding locking pin 146. Again, the bores 140 and 142 permit the device to be slidingly received by a guide wire during deployment of the device 130. The guide wire, during deployment, is confined within the channel 138. [0068] The device 130 still further includes a bend 50 at its distal end 134. As will be noted, the distal end 134 extends beyond the crossover point 19 of the circumflex artery 17 and the coronary sinus 14. However, because of the bend 150, the device is precluded from exerting constricting pressure on the circumflex artery 17 even though it extends over the crossover point 19. The device 130 may be implanted using the assembly as previously described. [0069]FIG. 10 shows still another mitral valve therapy device 230 embodying the present invention. Like the device 30 of FIG. 2, the device 230 is elongated and has an arched configuration to at least partially encircle the mitral valve 12 adjacent to the mitral valve annulus 20 when implanted in the coronary sinus 14. The device 230 has an unstressed preformed arched radius smaller than the radius of the dilated mitral valve annulus 20 to impart an inward, generally radial force on the mitral valve annulus 20 when implanted in the coronary sinus of the heart to return the mitral valve annulus 20 to its original or substantially original geometry permitting the cusps of the mitral valve to more fully come together for sealing the left atrium during left ventricular contraction. [0070] The device 230 has a cross section dimension to be received by the coronary sinus. It is preferably formed of any of the resilient materials previously described. [0071] The device 230 has a distal end 234 and a proximal end 236. Between the distal end 234 and proximal end 236 the device further includes a channel 238 which is aligned with a bore 242 extending through the proximal end 236. The proximal end 236 further includes an integral sleeve 244 which carries a protruding locking pin 246. The bore 242 permits the device to be slidingly received by the guide wire during deployment of the device 230. The guide wire, during deployment, is confined within the channel 238. The assembly 50 of FIGS. 3 and 4 including the guide wire 52, guide tube 54, and elongated introducer 56 may be utilized as described for deploying the device 230. Here, however, only one end of the device need be slidingly received by the guide wire 52 since the device is well confined within the guide tube 54 and the guide wire 52 is confined within the channel 238. [0072] As can thus be seen from the foregoing, the present invention provides a new and improved device, assembly and method for treating mitral regurgitation. The device may be employed with only percutaneous techniques. Further, the mitral valve therapy device may be implanted in a manner which avoids the crossover point of the circumflex artery and coronary sinus. Lastly, the effectiveness of the therapy may be immediately deduced during the implant procedure and permits substitution of devices for optimized results. [0073] While particular embodiments of the present invention have been shown and described, modifications may be made, and it is therefore intended in the appended claims to cover all such changes and modifications which fall within the true spirit and scope of the invention. BRIEF DESCRIPTION OF THE DRAWINGS [0034] The features of the present invention which are believed to be novel are set forth with particularity in the appended claims. The invention, together with further aspects and advantages thereof, may best be understood by making reference to the following description taken in conjunction with the accompanying drawings, and the several figures of which like reference numerals identify identical elements, and wherein: [0035]FIG. 1 is a superior view of a human heart with the atria removed; [0036]FIG. 2 is a perspective view of a mitral valve annulus constricting device embodying the present invention; [0037]FIG. 3 is a perspective view of an assembly for deploying a mitral valve constricting device in accordance with a preferred embodiment of the present invention; [0038]FIG. 4 is another perspective view of the assembly of FIG. 3; [0039]FIG. 5 is a superior view of a human heart similar to that of FIG. 1 and illustrating a method of determining the crossover point of the circumflex artery and the coronary sinus in accordance with a preferred embodiment of the present invention; [0040]FIG. 6 is another view of a human heart illustrating the method of determining the crossover point of the circumflex artery and the coronary sinus in accordance with the present invention; [0041]FIG. 7 is another superior view of a human heart illustrating deployment of a mitral valve therapy device in accordance with the preferred embodiment of the present invention; [0042]FIG. 8 is another superior view of a human heart illustrating an implanted mitral valve therapy device embodying the present invention; [0043]FIG. 9 is another superior view of a human heart illustrating another mitral valve therapy device embodying the present invention implanted in the heart; [0044]FIG. 10 is a perspective view of another mitral valve annulus device embodying the present invention.
Referenziert von Zitiert von PatentEingetragen Ver�ffentlichungsdatum Antragsteller TitelUS66562215. Febr. 20022. Dez. 2003Viacor, Inc.Method and apparatus for improving mitral valve functionUS667670214. Mai 200113. Jan. 2004Cardiac Dimensions, Inc.Mitral valve therapy assembly and methodUS679367326. Dez. 200221. Sept. 2004Cardiac Dimensions, Inc.System and method to effect mitral valve annulus of a heartUS679700111. M�rz 200228. Sept. 2004Cardiac Dimensions, Inc.Device, assembly and method for mitral valve repairUS68245628. Mai 200230. Nov. 2004Cardiac Dimensions, Inc.Body lumen device anchor, device and assemblyUS689035322. M�rz 200210. Mai 2005Viacor, Inc.Method and apparatus for reducing mitral regurgitationUS69084785. Dez. 200121. Juni 2005Cardiac Dimensions, Inc.Anchor and pull mitral valve device and methodUS69084823. Mai 200221. Juni 2005Edwards Lifesciences CorporationThree-dimensional annuloplasty ring and templateUS69491221. Nov. 200127. Sept. 2005Cardiac Dimensions, Inc.Focused compression mitral valve device and methodUS69602292. Mai 20031. Nov. 2005Cardiac Dimensions, Inc.Device and method for modifying the shape of a body organUS696692610. Sept. 200322. Nov. 2005Cardiac Dimensions, Inc.Mitral valve therapy assembly and methodUS697699530. Jan. 200220. Dez. 2005Cardiac Dimensions, Inc.Fixed length anchor and pull mitral valve device and methodUS698902830. Jan. 200224. Jan. 2006Edwards Lifesciences AgMedical system and method for remodeling an extravascular tissue structureUS699795124. Dez. 200214. Febr. 2006Edwards Lifesciences AgMethod and device for treatment of mitral insufficiencyUS70049586. M�rz 200228. Febr. 2006Cardiac Dimensions, Inc.Transvenous staples, assembly and method for mitral valve repairUS70116825. Aug. 200314. M�rz 2006Edwards Lifesciences AgMethods and apparatus for remodeling an extravascular tissue structureUS703733418. Juli 20032. Mai 2006Mitralign, Inc.Method and apparatus for catheter-based annuloplasty using local plicationsUS705248725. Okt. 200230. Mai 2006Viacor, Inc.Method and apparatus for reducing mitral regurgitationUS712542027. Mai 200324. Okt. 2006Viacor, Inc.Method and apparatus for improving mitral valve functionUS714436311. Okt. 20025. Dez. 2006Extensia Medical, Inc.Systems for heart treatmentUS716612724. Sept. 200423. Jan. 2007Mitralign, Inc.Tissue fastening systems and methods utilizing magnetic guidanceUS71792822. Mai 200320. Febr. 2007Cardiac Dimensions, Inc.Device and method for modifying the shape of a body organUS718626429. M�rz 20026. M�rz 2007Viacor, Inc.Method and apparatus for improving mitral valve functionUS724131014. Jan. 200310. Juli 2007Viacor, Inc.Method and apparatus for reducing mitral regurgitationUS727067624. Aug. 200418. Sept. 2007Cardiac Dimensions, Inc.Mitral valve therapy device, system and methodUS729414829. Apr. 200413. Nov. 2007Edwards Lifesciences CorporationAnnuloplasty ring for mitral valve prolapseUS73144853. Febr. 20031. Jan. 2008Cardiac Dimensions, Inc.Mitral valve device using conditioned shape memory alloyUS73167085. Dez. 20028. Jan. 2008Cardiac Dimensions, Inc.Medical device delivery systemUS736799114. Juni 20046. Mai 2008Edwards Lifesciences CorporationConformal tricuspid annuloplasty ring and templateUS748514315. Nov. 20023. Febr. 2009Abbott Cardiovascular Systems Inc.Apparatuses and methods for heart valve repairUS75072525. Aug. 200324. M�rz 2009Edwards Lifesciences AgAdjustable transluminal annuloplasty systemUS757559522. M�rz 200618. Aug. 2009Edwards Lifesciences CorporationAnnuloplasty ring and holder combinationUS759182628. Dez. 200022. Sept. 2009Cardiac Dimensions, Inc.Device implantable in the coronary sinus to provide mitral valve therapyUS78420851. Sept. 200630. Nov. 2010Edwards Lifesciences CorporationAnnuloplasty ring and holder combinationUS78790875. Okt. 20071. Febr. 2011Edwards Lifesciences CorporationMitral and tricuspid annuloplasty ringsUS793514530. Juni 20043. Mai 2011Edwards Lifesciences CorporationAnnuloplasty ring for ischemic mitral valve insuffuciencyUS79429279. M�rz 200517. Mai 2011Baker Medical Research InstituteTreating valve failureUS79511962. Febr. 200631. Mai 2011Edwards Lifesciences CorporationAnnuloplasty ring for mitral valve prolapseUS811415514. Apr. 200814. Febr. 2012Edwards Lifesciences CorporationAnnuloplasty ring with offset free endsUS812380014. Apr. 200528. Febr. 2012Edwards Lifesciences CorporationThree-dimensional annuloplasty ring and templateUS823605018. Dez. 20077. Aug. 2012Edwards Lifesciences CorporationMitral annuloplasty ring having upward bowsWO2003049648A23. Dez. 200219. Juni 2003Adams, John, M.Anchor and pull mitral valve device and methodDrehenOriginalbildGoogle-Startseite - Sitemap - USPTO-Bulk-Downloads - Datenschutzerkl�rung - Nutzungsbedingungen - �ber Google Patente - Feedback gebenDaten bereitgestellt von IFI CLAIMS Patent Services.© 2012 Google